Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Fatemeh MohammadiGolale RostamiDlnya AssadMohammad ShafieiMohammad HamidHasan JalaeikhooPublished in: Laboratory medicine (2022)
Our study results suggest the influence of SLC22A1 and SLCO1B3 polymorphisms and the interaction of smoking on CML development and IM response.